When was Aignostics founded?

Aignostics was founded in 2018 and raised its 1st funding round 2 years after it was founded.

Where is Aignostics located?

Aignostics is headquartered in Berlin, Germany.

Who is the current CEO of Aignostics?

Viktor Matyas of Aignostics. They have also founded 1 company.

Which legal entities is Aignostics associated with?

Aignostics is associated with Aignostics Gmbh and 1 other.

How many employees does Aignostics have?

As of Sep 30, 2026, the latest employee count at Aignostics is 110.

Is Aignostics a funded company?

Aignostics is a funded company, having raised a total of $53.9M across 4 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Aug 28, 2020.

When was the latest funding round of Aignostics?

Aignostics' latest funding was a $***** Series B round on Oct 29, 2024, with participation from 7 investors.

Where does Aignostics rank among its competitors?

Aignostics ranks 9th amongst 265 active competitors, of which 78 are funded. It stands 7th in terms of total funding among its competitors. The most recent competitor to raise funding was DeepWise, which secured an undisclosed amount in Jun, 2026.

Who are the top competitors of Aignostics?

Aignostics' top competitors include PathAI, Lunit and Aiforia. Among them, DeepWise secured the most recent funding round in June, 2026.

Aignostics - 2026 Company Profile, Team, Funding, Competitors & Financials

Aignostics is a series B company based in Berlin (Germany), founded in 2018 by Viktor Matyas, Klaus-Robert Muller and Maximilian Alber. It operates as a Developer of artificial intelligence software for biomedical image analysis applications. Aignostics has raised $53.9M in funding from investors like Wellington Partners Venture Capital, Boehringer Ingelheim Venture Fund and Athos. The company has 265 active competitors, including 78 funded and 15 that have exited. Its top competitors include companies like PathAI, Lunit and Aiforia.

Company Details

Developer of artificial intelligence software for biomedical image analysis applications. This technology processes pathology samples to identify drug targets and biomarkers. The software utilizes foundation models to generate embeddings for downstream analysis of tumor microenvironments. These tools support research in drug development and clinical diagnostics by predicting expression patterns and classifying cell types within tissue images.

Website: www.aignostics.com/
Social
Email ID: *****@aignostics.com

Key Metrics

Founded Year

2018

Location

Berlin, Germany

Stage

Series B

Total Funding

$53.9M in 4 rounds

Latest Funding Round

Series B, Oct 29, 2024, $*****

Investors

Wellington Partners Venture Capital & 10 more

Ranked

9^th among 265 active competitors

Employee Count

110 as on Sep 30, 2026

Similar Companies

OpenEvidence & 3046 more

View Aignostics' full profile

Aignostics is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
Aignostics Gmbh CIN: F1103_HRB215748B , Germany, Active	Mar 12, 2020	-	-
Aignostics Gmbh CIN: HRB215748 , Germany, Active	Mar 11, 2020	-	25 (As on Dec 31, 2021)

Aignostics has raised a total funding of $53.9M over 4 rounds. Its first funding round was on Aug 28, 2020. Its latest funding round was a Series B round on Oct 29, 2024 for $*****. 7 investors participated in its latest round. Aignostics has 11 institutional investors.

Here is the list of recent funding rounds of Aignostics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 29, 2024	2368633	Series B	5983797	7250174	3937782	8502279
Mar 06, 2023	8615865	Grant (prize money)	4751284	8992965	2942540	IBB Ventures
Sep 15, 2022	5708555	Series A	3016117	7433919	Wellington Partners Venture Capital	Boehringer Ingelheim Venture Fund & 3 more

Access funding benchmarks and valuations. Sign up today!

View details of Aignostics's funding rounds and investors

The founders of Aignostics are Viktor Matyas, Klaus-Robert Muller and Maximilian Alber. Viktor Matyas is the CEO of Aignostics.

Here are the details of Aignostics' key team members:

Viktor Matyas: Co-Founder & CEO of Aignostics. They serve on the board of 1 company.
Contact Info: 1 email address
Klaus-Robert Muller: Co-Founder of Aignostics.
Contact Info: 1 email address
Maximilian Alber: Co-Founder & CTO of Aignostics.
Contact Info: 1 email address

View details of Aignostics's Founder profiles and Board Members

Aignostics' employee count trend

Aignostics has 110 employees as of Sep 26. Here is Aignostics's employee count trend over the years:

Uncover Aignostics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Aignostics include PathAI, Lunit and Aiforia. Here is the list of Top 10 competitors of Aignostics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	PathAI 2016, Boston (United States), Series C	Provider of digital pathology image management system for clinical labs	$255M	General Catalyst, General Atlantic & 22 others	72/100
2nd	Lunit 2013, Seoul (South Korea), Public	Developer of medical software for cancer screening and oncology diagnostics	$135M	InterVest, Shinhan Investment Corp & 26 others	67/100
3rd	Aiforia 2014, Helsinki (Finland), Public	Provider of an AI and cloud-based, deep learning image analysis platform in all therapy areas	$23M	Ascend Capital Partners, Businessfinland & 8 others	66/100
4th	Ibex 2016, Tel Aviv (Israel), Series C	Provider of AI-powered diagnostic solutions for pathology	$114M	83NORTH, Kreos Capital & 7 others	64/100
5th	Valar Labs 2021, Palo Alto (United States), Series A	Developer of AI diagnostics for predicting cancer treatment response likelihood	$26.1M	Andreessen Horowitz, DCVC & 19 others	63/100
6th	Proscia 2014, Philadelphia (United States), Acquired	Provider of an AI and cloud-based digital pathology solution for cancer diagnosis	$129M	Triangle Peak Partners, TEDCO & 22 others	62/100
7th	Techcyte 2014, Orem (United States), Series B	Artificial intelligence (AI) based image analysis platform for pathologists	$50.4M	ARUP Laboratories, Zoetis & 2 others	62/100
8th	Nucle AI 2017, Chicago (United States), Series B	AI-assisted platform for image analysis	$60M	Vertex Ventures Israel, Sanofi Ventures & 9 others	61/100
9th	Aignostics 2018, Berlin (Germany), Series B	Developer of artificial intelligence software for biomedical image analysis applications	$53.9M	Wellington Partners Venture Capital, Boehringer Ingelheim Venture Fund ... & 9 others	61/100
10th	DeepWise 2017, Beijing (China), Series D	Developer of AI-based radiology image solutions primarily for cancer diagnosis	$115M	Legend Capital, CICC Capital & 18 others	59/100